Eutilex.Co.Ltd
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headqua… Read more
Eutilex.Co.Ltd (263050) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.083x
Based on the latest financial reports, Eutilex.Co.Ltd (263050) has a cash flow conversion efficiency ratio of -0.083x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.41 Billion) by net assets (₩28.91 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eutilex.Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Eutilex.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eutilex.Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eutilex.Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CABKA N.V. SHS EO-01
F:7GW
|
N/A |
|
AWC Berhad
KLSE:7579
|
0.141x |
|
Haesung Optics Co. Ltd
KQ:076610
|
-0.340x |
|
TRF Limited
NSE:TRF
|
0.128x |
|
Madras Fertilizers Limited
NSE:MADRASFERT
|
13.143x |
|
Rocketboots Ltd
AU:ROC
|
-19893.119x |
|
BEGHELLI S.P.A. EO -05
F:BGQ
|
N/A |
|
SAAM Energy Development Public Company Limited
BK:SAAM
|
0.002x |
Annual Cash Flow Conversion Efficiency for Eutilex.Co.Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Eutilex.Co.Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩39.94 Billion | ₩-21.40 Billion | -0.536x | -26.63% |
| 2023-12-31 | ₩60.44 Billion | ₩-25.58 Billion | -0.423x | -24.17% |
| 2022-12-31 | ₩87.75 Billion | ₩-29.90 Billion | -0.341x | +13.88% |
| 2021-12-31 | ₩68.38 Billion | ₩-27.06 Billion | -0.396x | -30.05% |
| 2020-12-31 | ₩58.51 Billion | ₩-17.80 Billion | -0.304x | -42.14% |
| 2019-12-31 | ₩62.83 Billion | ₩-13.45 Billion | -0.214x | -62.31% |
| 2018-12-31 | ₩77.49 Billion | ₩-10.22 Billion | -0.132x | -24.07% |
| 2017-12-31 | ₩51.13 Billion | ₩-5.44 Billion | -0.106x | +25.20% |
| 2016-12-31 | ₩25.87 Billion | ₩-3.68 Billion | -0.142x | -- |